Relationship between k -RAS mutation and resistance to gefinitib treatment in patients with non -small -cell lung cancer
10.13699/j.cnki.1001-6821.2014.10.008
- VernacularTitle:k -RAS 基因突变与吉非替尼治疗非小细胞肺癌疗效的相关性研究
- Author:
Wen-Juan WU
1
;
Liang GU
Author Information
1. 浙江医院 呼吸内科
- Keywords:
non -small -cell lung carcer;
gefintib;
k -RAS gene
- From:
The Chinese Journal of Clinical Pharmacology
2014;(10):898-900
- CountryChina
- Language:Chinese
-
Abstract:
Objective To evaluate the relationship between k -RAS mutation and the resistance to gefinitib treatment in patients with non -small -cell lung cancer (NSCLC).Methods 88 patients with NSCLC treated with gefinitib were analyzed respectively.The mutation of codon 12 and 13, located in exon1 and exon 2, was detected by PCR and DAN sequencing in the 88 NSCLC.The response between k -RAS mutation and the resistance to gefinitib treatment in patients with NSCLC was ana -lyzed.Results Fifteen patients were found mutated coden 12 /13, with an mutation frequency of 17.0% (15 /88).The objective response rate (ORR) was 22.7%(20 /88) with 4 cases of complete response and 16 cases of partial response, which indicating the ORR was much higher in patients with wild -type k -RAS gene than that in patients with mutated k -RAS genen (P <0.05).Conclusion NSCLC patients with mutated k -RAS gene can not benefit from EGFR -TIK treatment.
